London, UK, 28 June 2012 Sinclair IS Pharma (“Sinclair IS” or the “Company”), the international specialty pharma company, announces its first co-promotion agreement for Kelo-cote® (silicone-based scar reduction gel/spray), with Galderma. The partnership with Galderma’s Italian affiliate will be for 5 years, and includes gel and spray presentations as well as new Kelo-cote® line extensions.
Sinclair IS first licensed the rights to market Kelo-cote® in leading European markets in February 2011, before acquiring the asset globally through the purchase of ABT Inc. in December 2011. The Company remains very optimistic for the continued strong growth of this highly strategic franchise in both Europe and emerging markets, and now believes the potential to be sufficient to merit the introduction of partners to complement proprietary sales teams.
CEO Chris Spooner comments – “Kelo-cote® is a major growth driver for Sinclair IS and has attracted considerable interest from patients and physicians, and within the dermatology industry. Galderma is a pre-eminent player in the dermatology industry, and we are delighted to have the company co-promote our flagship brand in Italy. Against a backdrop of increasing interest in silicone-based scar reduction therapies and Kelo-cote® in particular, we are confident of the continued strong performance of the product, driven by multiple clinical uses, new market launches and line extensions”.
For further information please contact:
Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920
Jefferies International Limited (NOMAD and Broker) Tel: +44 (0) 20 7029 8000
FTI Consulting Tel: +44 (0) 20 7831 3113
About Sinclair IS Pharma Plc www.sinclairispharma.com
Sinclair IS Pharma plc is an international specialty pharmaceutical company providing solutions to treat wounds, dermatological and oral diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is present in France, UK, Italy, Germany and Spain, and an extensive marketing partner network across selected developed & emerging markets.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.
|SINCLAIR IS PHARMA PLC.||Euronext Paris||0.27||0.00%||0|